Altor BioScience Corporation Awarded $3 MM SBIR Bridge Grant by National Cancer Institute to Advance Clinical Trials for its Targeted Cancer Therapeutic ALT-801

Published: Sep 25, 2009

MIRAMAR, Fla.--(BUSINESS WIRE)--Altor BioScience Corporation announced today that it has been awarded a Small Business Innovation Research (SBIR) Phase II Bridge Grant by the National Cancer Institute (NCI). The award of $3 MM over three years will help Altor further its clinical development of ALT-801, a novel tumor-targeted immunotherapeutic designed to improve the efficacy and safety of the FDA-approved anticancer cytokine, interleukin-2 (IL-2). This funding will initially be used to support a clinical trial with a novel biochemotherapy regimen of ALT-801 with cisplatin in patients with metastatic melanoma. Altor also plans to use the funding to launch other clinical trials for ALT-801 in renal cell carcinoma, head & neck cancer and prostate cancer. In a recently completed Phase I/IIa trial, certain patients with these cancers were found to benefit from treatment with ALT-801.

Back to news